Baxter Submits Application for FDA Approval of OBI-1 for Patients with Acquired Hemophilia A

16-12-2013 Business Wire HealthComments (0)

BaxterPharmaceutical

Baxter has submitted a BLA to the U.S. FDA for the approval of OBI-1 for patients with acquired hemophilia A. Phase 2/3 data supporting the submission were presented during the ASH annual meeting.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top